Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Amortizatization of Intangibles (2021 - 2025)

Janux Therapeutics (JANX) has disclosed Amortizatization of Intangibles for 5 consecutive years, with $3.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Amortizatization of Intangibles rose 20.4% to $3.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $17.6 million, a 66.03% increase, with the full-year FY2025 number at $17.6 million, up 66.03% from a year prior.
  • Amortizatization of Intangibles was $3.5 million for Q4 2025 at Janux Therapeutics, down from $4.6 million in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $5.2 million in Q2 2025 to a low of $24000.0 in Q1 2022.
  • A 5-year average of $2.0 million and a median of $1.8 million in 2023 define the central range for Amortizatization of Intangibles.
  • Peak YoY movement for Amortizatization of Intangibles: surged 6891.67% in 2023, then increased 6.5% in 2024.
  • Janux Therapeutics' Amortizatization of Intangibles stood at $58000.0 in 2021, then soared by 2127.59% to $1.3 million in 2022, then skyrocketed by 59.52% to $2.1 million in 2023, then surged by 42.02% to $2.9 million in 2024, then rose by 20.4% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Amortizatization of Intangibles are $3.5 million (Q4 2025), $4.6 million (Q3 2025), and $5.2 million (Q2 2025).